Dabur eyes deals for anti-cancer drug
Dabur India has initiated negotiations with two global pharmaceutical giants for co-licensing its anti-cancer DRF 7295 molecule for drug development and marketing.
Dabur India has initiated negotiations with two global pharmaceutical giants for co-licensing its anti-cancer DRF 7295 molecule for drug development and marketing.